| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | -0.16 | 1e-05 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.16 | 2e-05 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | 0.16 | 7e-05 |
| mRNA | Platin | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0003 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0003 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.17 | 0.0004 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.1 | 0.0005 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0007 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0007 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |